journal article·2026-07-01Open access

A Plant Photoregulator‐Inspired S‐Type Heterojunction System for Diabetic Keratopathy via Tri‐Modal Light‐Driven Immunometabolic Reprogramming, Tissue Repair, and Antibacterial Activity

Mengzhen Zhao, Zhibin Zhou, Yuxuan Wei, Xiangfan Huang, Zhiyong Zhou, Jiaheng Chen, Haoxin Cheng, Xiaotian Hu, Xiaolei Wang

Abstract

ABSTRACT Diabetic keratopathy (DK) is a prevalent ocular surface complication of diabetes, frequently unnoticed until significant structural and functional deterioration occurs. Chronic hyperglycemic stress promotes inflammation in the corneal epithelial‐neural‐immune (epineuroimmune) unit, impeding tissue recovery and increasing infection susceptibility. To address this metabolic–immune–infection imbalance, we developed a light‐regulated biomimetic catalytic platform (WCN x ‐Rh2) that integrates glucose degradation and monitoring, immune‐modulated epithelial‐neural regeneration, and antibacterial defense. This platform features an S‐scheme heterojunction (WCN x ) composed of graphitic carbon nitride and tungsten oxide, enabling visible‐light (VIS)‐driven glucose degradation, dark‐state colorimetric detection, and near‐infrared (NIR) photothermal antibacterial activity. Complementarily, the loaded ginsenoside Rh2—identified via systematic screening—inhibits the Nucleotide‐binding and oligomerization domain (NOD)‐like receptor signaling pathway. The combined action of WCN x and Rh2 reduces advanced glycation end products (AGEs), reactive oxygen species (ROS), and inflammatory signaling, reprogramming dendritic cell function to restore epineuroimmune homeostasis and drive tissue repair. These functions were validated in two animal models. In diabetic mice, VIS‐irradiated WCN x ‐Rh2 accelerated corneal epithelial and nerve recovery. In a diabetic keratitis model, NIR‐activated WCN x ‐Rh2 enabled effective corneal bacterial eradication and tissue repair. Overall, this work establishes a light‐driven metabolic‐modulation biomimetic paradigm and proposes an integrated strategy for managing DK.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Corneal Surgery and Treatments · Ocular Surface and Contact Lens · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemistry and Chemical Engineering Nanchang University Nanchang Jiangxi P. R. China

Department of General Surgery The First Affiliated Hospital of Nanchang University Nanchang Jiangxi P. R. China

The National Engineering Research Center for Bioengineering Drugs and the Technologies Institute of Translational Medicine Nanchang University Nanchang Jiangxi P. R. China

Center for Molecular Diagnosis and Precision Medicine The First Affiliated Hospital of Nanchang University Nanchang Jiangxi P. R. China

Funding

National Natural Science Foundation of China

References (77)

Show source-provided references
1. Diabetic Keratopathy
2. Corneal Neuropathy: an Underrated Manifestation of Diabetes Mellitus
3. 10.1186/s40662‐023‐00370‐110.1186/s40662‐023‐00370‐1 ↗
4. 10.1016/j.preteyeres.2019.05.00310.1016/j.preteyeres.2019.05.003 ↗
5. 10.2147/OPTH.S18518410.2147/OPTH.S185184 ↗
6. A Novel Treatment for Neurotrophic Corneal Ulcer Using Topical Cenegermin (OXERVATE™) Containing Recombinant Human Nerve Growth Factor
7. 10.1016/j.ophtha.2019.08.02010.1016/j.ophtha.2019.08.020 ↗
8. 10.1016/j.survophthal.2020.02.00510.1016/j.survophthal.2020.02.005 ↗
9. 10.1016/j.biopha.2023.11452310.1016/j.biopha.2023.114523 ↗
10. 10.1016/j.preteyeres.2021.10103910.1016/j.preteyeres.2021.101039 ↗
11. 10.7150/ijbs.6321910.7150/ijbs.63219 ↗
12. 10.1038/srep3641410.1038/srep36414 ↗
13. 10.1016/j.jtos.2025.02.01010.1016/j.jtos.2025.02.010 ↗
14. Neurotrophic Factors and Corneal Nerve Regeneration10.4103/1673-5374.213534 ↗
15. 10.1172/JCI8509710.1172/JCI85097 ↗
16. 10.1167/iovs.16‐2137210.1167/iovs.16‐21372 ↗
17. 10.1016/S2213‐8587(25)00135‐410.1016/S2213‐8587(25)00135‐4 ↗
18. 10.4093/dmj.2025.050810.4093/dmj.2025.0508 ↗
19. 10.1002/adma.20241338510.1002/adma.202413385 ↗
20. 10.1002/adfm.20241111710.1002/adfm.202411117 ↗
21. 10.1038/s41467‐025‐60448‐310.1038/s41467‐025‐60448‐3 ↗
22. 10.1016/j.apsb.2024.01.00310.1016/j.apsb.2024.01.003 ↗
23. 10.1038/s41467‐025‐64242‐z10.1038/s41467‐025‐64242‐z ↗
24. 10.1038/s41467‐019‐08731‐y10.1038/s41467‐019‐08731‐y ↗
25. 10.1038/s41467‐022‐33475‐710.1038/s41467‐022‐33475‐7 ↗
26. 10.1021/acsnano.4c1234810.1021/acsnano.4c12348 ↗
27. 10.1016/j.phymed.2025.15740710.1016/j.phymed.2025.157407 ↗
28. 10.1097/JS9.000000000000239410.1097/JS9.0000000000002394 ↗
29. 10.1016/j.jare.2025.10.07010.1016/j.jare.2025.10.070 ↗
30. 10.1016/j.cpan.2024.12.00210.1016/j.cpan.2024.12.002 ↗
31. 10.1038/s41392‐023‐01329‐310.1038/s41392‐023‐01329‐3 ↗
32. 10.1126/sciadv.ads958110.1126/sciadv.ads9581 ↗
33. 10.1038/s41586‐024‐07237‐y10.1038/s41586‐024‐07237‐y ↗
34. Adaptive Immunity of Materials: Implications for Tissue Healing and Regeneration10.1016/j.bioactmat.2024.07.027 ↗
35. Anisotropic Structure of Nanofiber Hydrogel Accelerates Diabetic Wound Healing via Triadic Synergy of Immune‐Angiogenic‐Neurogenic Microenvironments10.1016/j.bioactmat.2025.01.004 ↗
36. 10.1002/adma.20230527710.1002/adma.202305277 ↗
37. 10.1021/acsnano.4c1844410.1021/acsnano.4c18444 ↗
38. 10.1002/adma.20241411110.1002/adma.202414111 ↗
39. 10.1021/acsnano.9b0987110.1021/acsnano.9b09871 ↗
40. Photothermal Therapy with Regulated Nrf2/NF‐κB Signaling Pathway for Treating Bacteria‐Induced Periodontitis10.1016/j.bioactmat.2021.07.033 ↗
41. 10.1016/j.xplc.2023.10064410.1016/j.xplc.2023.100644 ↗
42. 10.1002/adfm.20230631910.1002/adfm.202306319 ↗
43. 10.1016/j.apcatb.2020.11952010.1016/j.apcatb.2020.119520 ↗
44. 10.1002/advs.20240360710.1002/advs.202403607 ↗
45. 10.1002/anie.20250632210.1002/anie.202506322 ↗
46. 10.1002/adfm.20241194110.1002/adfm.202411941 ↗
47. 10.1016/j.cej.2023.14829710.1016/j.cej.2023.148297 ↗
48. 10.1007/s10934‐025‐01771‐410.1007/s10934‐025‐01771‐4 ↗
49. 10.1002/adma.20240856010.1002/adma.202408560 ↗
50. XPS, XES and XAS Studies of the Electronic Structure of Tungsten Oxides10.1016/S0925-8388(00)00697-6 ↗
51. 10.1016/j.apsusc.2020.14766710.1016/j.apsusc.2020.147667 ↗
52. 10.1038/s41467‐024‐47123‐910.1038/s41467‐024‐47123‐9 ↗
53. 10.1002/adfm.20251667110.1002/adfm.202516671 ↗
54. 10.1002/advs.20251013310.1002/advs.202510133 ↗
55. 10.1016/j.biomaterials.2025.12341710.1016/j.biomaterials.2025.123417 ↗
56. 10.1007/s11892‐013‐0453‐110.1007/s11892‐013‐0453‐1 ↗
57. 10.1016/j.redox.2013.12.01610.1016/j.redox.2013.12.016 ↗
58. 10.1038/sj.jid.570007010.1038/sj.jid.5700070 ↗
59. 10.1038/s41586‐025‐09000‐310.1038/s41586‐025‐09000‐3 ↗
60. High Glucose Enhances Progression of Cholangiocarcinoma Cells via STAT3 Activation10.1038/srep18995 ↗
61. 10.1111/jdi.1372210.1111/jdi.13722 ↗
62. 10.3390/ijms2217928910.3390/ijms22179289 ↗
63. 10.3390/ijms23221428910.3390/ijms232214289 ↗
64. 10.1038/s41598‐022‐25722‐010.1038/s41598‐022‐25722‐0 ↗
65. 10.1038/s41598‐020‐64489‐010.1038/s41598‐020‐64489‐0 ↗
66. 10.1039/C6CS00636A10.1039/C6CS00636A ↗
67. 10.3390/vaccines404004510.3390/vaccines4040045 ↗
68. 10.1248/bpb.28.38310.1248/bpb.28.383 ↗
69. 10.1111/j.1476‐5381.2010.00768.x10.1111/j.1476‐5381.2010.00768.x ↗
70. 10.1016/j.taap.2018.05.01410.1016/j.taap.2018.05.014 ↗
71. 10.1016/j.bbamem.2024.18436610.1016/j.bbamem.2024.184366 ↗
72. 10.1016/j.celrep.2024.11370010.1016/j.celrep.2024.113700 ↗
73. 10.1038/s41467‐025‐57511‐410.1038/s41467‐025‐57511‐4 ↗
74. 10.1158/0008‐5472.CAN‐22‐100210.1158/0008‐5472.CAN‐22‐1002 ↗
75. 10.1126/scisignal.adh117810.1126/scisignal.adh1178 ↗
76. 10.1002/adma.20240822110.1002/adma.202408221 ↗
77. 10.1002/adma.20241920910.1002/adma.202419209 ↗